Moleculin Biotech Stock
Moleculin Biotech, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Walter V. Klemp
- Employees
- 17
- Market cap
- $1 M
- IPO
- 02/06/2016
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy…
Moleculin Biotech stock: price history
1D
-24.2%
1W
-36.6%
1M
-62.1%
6M
-88.4%
YTD
-91.5%
1Y
-97.7%
2Y
-99.5%
5Y
-100.0%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~27% weaker price swings than usual
Ask the agents about Moleculin Biotech
Analyst assessment of Moleculin Biotech
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 28/08/2026
Moleculin Biotech stock metrics
P/E
-0.02
P/B
0.14
EV/EBITDA
0.18
RETURN ON EQUITY
-65.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.2%
FLOAT SHARES
5,291,930
AVG. DAILY VOLUME (30D)
990,675
Insider transactions (SEC)
Foster Jonathan P.
Foster Jonathan P.
KLEMP WALTER V
KLEMP WALTER V
KLEMP WALTER V
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Moleculin Biotech stock
What does Moleculin Biotech do?
Moleculin Biotech, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Walter V. Klemp, the company employs around 17 people.
The IPO was on 02/06/2016; the stock trades on NASDAQ under the ticker MBRX.
What do analysts say about Moleculin Biotech stock?
4 analysts rate the stock, the consensus is Buy (as of 28/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Moleculin Biotech report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -27% stronger than usual.
Does Moleculin Biotech pay a dividend?
No, Moleculin Biotech currently does not pay a dividend.
Which stocks are comparable to Moleculin Biotech?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Moleculin Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Moleculin Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.